UnitedHealth Group raised full-year earnings guidance to at least $20.50 per share after third-quarter operating earnings jumped 53 percent, driven by a 150-basis-point improvement in its medical cost ratio despite revenues that fell slightly year-over-year.
Third-quarter revenues were $112.7 billion, down from $113.2 billion in the same quarter last year. Earnings from operations reached $6.6 billion compared to $4.3 billion a year earlier. The medical care ratio improved to 88.4 percent from 89.9 percent, a shift the company attributed to medical cost management initiatives, benefit design changes, pricing discipline, and care delivery enhancements. The company recorded $610 million in net favorable prior period reserve development related to 2026 dates of service. Operating costs as a percentage of revenue fell to 12.8 percent from 13.5 percent, reflecting what the company described as realized operating efficiencies partially offset by investments in technology and care delivery.
UnitedHealthcare, the insurance segment, generated $86.3 billion in revenues and $2.8 billion in operating earnings. Optum, the health services and technology division, drove $66.9 billion in revenues and $3.7 billion in earnings while serving over 120 million patients and consumers. Cash flow from operations was $5.1 billion, or 1.2 times net income.
What it means
The quarter presents a paradox: UnitedHealth’s top line contracted while profitability expanded sharply. The driver is operational rather than cyclical. The medical cost ratio compression of 150 basis points suggests the company’s cost-management initiatives, tighter benefit design, prior authorization restrictions, and value-based care arrangements, are producing measurable results faster than pricing power alone would deliver. The $610 million favorable reserve development is a one-time tailwind that improved the quarter but does not recur; strip it out and the underlying medical ratio improvement remains substantial.
The operating cost ratio decline is the second pillar. A 70-basis-point improvement in operating efficiency while simultaneously investing in technology and clinician experience suggests UnitedHealth is extracting productivity gains from its existing base. The company repurchased $5.0 billion of stock year-to-date and paid $6.2 billion in dividends, indicating confidence in cash generation even as it funds transformation.
The raised guidance, affirmed at “at least $20.50 per share” adjusted earnings for full year 2026, signals management’s belief that the medical cost discipline will hold through year-end. The open question is whether the 88.4 percent medical care ratio is sustainable or whether it reflects a favorable comparison quarter and reserve releases that will not repeat. The company’s debt-to-capital ratio of 41.7 percent sits slightly above its stated 40 percent target, suggesting limited room for large acquisitions but adequate capacity for organic investment.
Source: the company’s 8-K filed 2026-10-13 with the SEC.
For the standing yardsticks on UnitedHealth Group: the price tag, the filed record, and the four gauges, refreshed with each edition, see the BullScope Evidence Sheet: UnitedHealth Group.
